Oxford BioTherapeutics to Participate in Panel Discussion at Boehringer Ingelheim’s Upcoming Transforming Science Day: Europe The panel discussion will highlight OBT’s successful 10-year partnership with Boehringer Ingelheim and the foundations it has been built on Oxford, UK, San Jose, Calif., 19th September 2023 -...

Oxford BioTherapeutics and Boehringer Ingelheim Agree on 2 Year Extension to their Second Multi-Year Collaboration in Cancer Immunology Oxford, UK and San Jose, Calif., 25 May 2023 – Oxford BioTherapeutics Ltd. (OBT), a clinical stage oncology company with a pipeline of immuno-oncology and antibody-drug conjugate (ADC)-based...

Oxford BioTherapeutics announces Phase 1b trial in collaboration with GORTEC to investigate OBT076 in Adenoid Cystic Carcinoma (ACC) of the head and neck Trial will investigate OBT076 as monotherapy and in sequence with balstilimabCD205, OBT076’s target antigen, is overexpressed in ~ 80 % of ACC tumor biopsy samplesRecurrent or metastatic ACC patients...

Deem Announces Leadership Changes Oakland, CA, Nov. 17, 2020 (GLOBE NEWSWIRE) -- Deem, a leading mobile and cloud technology provider for the corporate travel industry and a wholly owned and independently operated subsidiary of...